Application of CPA6 gene or coding protein thereof in regulation and control of host anti-bovine enterovirus

The CRISPR/Cas9 technology constructed a bovine kidney cell model with CPA6 gene knockout, proving that the CPA6 gene plays an important role in anti-bovine enterovirus infection, solves the problem of effective control of bovine enterovirus infection, and provides new treatments and Prevention strategies.

CN119082090AActive Publication Date: 2024-12-06HUAZHONG AGRI UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411327049.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-12-06
Estimated Expiration
2044-09-23

AI Technical Summary

Technical Problem

Currently, effective treatments are lacking to control bovine enterovirus (BEV) infection, and few studies on the mechanisms of host-viral interactions have affected the health and productivity of cattle herds.

Method used

CRISPR/Cas9 gene editing technology is used to construct a CPA6 gene targeting vector targeting bovine kidney cell line. Cell model of CPA6 gene knockout is established through vector transfection and cell screening, proving that the CPA6 gene plays an important role in regulating host anti-BEV infection. and develop reagents for knocking out or silencing CPA6 genes to prepare anti-BEV drugs and cell models.

Benefits of technology

Successfully inhibited the infection and proliferation of the virus, established a cellular model that effectively resisted BEV infection, and for the first time, the CPA6 gene was discovered to regulate the host's anti-BEV infection ability, providing potential targets for prevention and treatment, and simplifying related research and drug screening processes. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082090A_ABST
    Figure CN119082090A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a carboxypeptidase 6 (CPA6) gene in regulation and control of a host for resisting a bovine enterovirus (BEV), and particularly discloses an application of a carboxypeptidase 6 (CPA6) gene in regulation and control of a host for resisting a bovine enterovirus (BEV). A CPA6 gene knockout bovine kidney cell line and an anti-BEV virus infection cell model are constructed by using a CRISPR / Cas9 gene editing technology, virology detection results show that the proliferation rate of BEV on gene knockout cells is significantly lower than that of wild cells, the antiviral effect of the cells disappears if the CPA6 gene is supplemented, and the cell model has a good anti-virus effect. It is indicated that the CPA6 gene plays an important role in regulating and controlling the host to resist BEV infection. The function of the CPA6 gene is identified from the cellular level, it is found for the first time that the gene can serve as a potential target for gene editing animal design to be applied to disease-resistant breeding, prevention and treatment of BEV infection, and the gene has great significance in reducing drug abuse and avoiding epidemic situations.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of prevention and treatment of animal infectious diseases, and specifically relates to the application of CPA6 gene in regulating host resistance to bovine enterovirus (BEV). Background Art

[0002] Bovine enterovirus (BEV) is a small RNA virus and one of the main pathogens causing respiratory and intestinal diseases in cattle. Infection caused by this virus can cause serious problems such as dyspnea, diarrhea, indigestion, and growth stagnation in cattle, which seriously affects the health and production efficiency of the cattle. The etiology and ecology of this virus still need further study, and there is currently no definite effective treatment. Therefore, in-depth research on the interaction between BEV and the host and identification of host factors related to viral infection are of great significance for the effective control of BEV infection.

[0003] Currently, a large number of studies focus on epidemiological surveys and related diagnostic methods and vaccine development, but few studies have examined the interaction mechanism between hosts and BEV. Today, CRISPR / Cas9 high-throughput screening technology has matured and has been used on a variety of mammals, successfully obtaining a large number of susceptibility genes for host-pathogen interactions. Studying the molecular mechanism of host gene-pathogen interaction and understanding the specific ways in which hosts and viruses interact can provide target molecules for the development of new vaccines and drugs and editing genes to modify disease-resistant varieties, providing a theoretical basis for the precise and efficient prevention and treatment of BEV infections.

[0004] Carboxypeptidase A6 (CPA6) was discovered in 2002 in a bioinformatics study of the human genome. Its main function is to have zinc ion (Zn) binding metallocarboxypeptidase activity, which has not been reported in cattle. Studies have shown that missense mutations in the CPA6 gene at the Arg36His and Asn271Ser sites can cause juvenile myoclonic epilepsy; increased methylation of the CPA6 promoter can cause temporal lobe epilepsy and febrile convulsions in patients; CPA6 is significantly upregulated in early oral squamous cell carcinoma and is considered a potential predictive target for active colitis; in addition, CPA6 is involved in the novel glucose-lowering mechanism of metformin. However, the antiviral infection function of CPA6 has not been reported. Summary of the invention

[0005] One of the purposes of the present invention is to provide a function of a CPA6 gene, especially its function in regulating host resistance to BEV infection.

[0006] To achieve the above purpose, the present invention uses CRISPR / Cas9 gene editing technology to construct a targeting vector targeting the CPA6 gene of a bovine kidney cell line (Madin-Darby bovine kidney, MDBK), and establishes a CPA6 gene knockout cell line and a cell model against BEV virus infection through vector transfection and cell screening. Virological detection results show that CPA6 gene knockout cells show significant resistance to BEV infection, the virus proliferation rate on gene knockout cells is significantly lower than that of wild-type cells, and the virus titer is significantly reduced, indicating that at the cellular level, CPA6 gene knockout effectively inhibits virus infection and proliferation; while complementing the CPA6 gene leads to the disappearance of the antiviral effect of the cell, indicating that the CPA6 gene plays an important role in regulating the host's antiviral ability. The present invention uses CRISPR / Cas9-mediated gene knockout method to establish a cell model that effectively resists BEV infection, confirming the role of the CPA6 gene as a target in antiviral infection. This strategy can be applied to the preparation of CPA6 gene-modified anti-BEV infected cells and animals and the development of new drugs.

[0007] The second object of the present invention is to provide a reagent for knocking out or silencing the CPA6 gene for use in the preparation of anti-BEV drugs, animal cells and varieties. The reagent includes: a Cas9 gene editing protein or an expression vector thereof, and an sgRNA or an expression vector thereof that guides the Cas9 gene editing protein to specifically bind to the CPA6 gene. However, the present invention is not limited to reagents developed based on CRISPR / Cas9 technology, and other reagents designed for knocking out and silencing the target CPA6 gene using other gene knockout or silencing methods known in the art are also within the scope of protection of the present invention.

[0008] The third object of the present invention is to provide an anti-BEV drug, which contains a reagent for knocking out or silencing the CPA6 gene. The reagent includes: a Cas9 gene editing protein or an expression vector thereof, and an sgRNA or an expression vector thereof that guides the Cas9 gene editing protein to specifically bind to the CPA6 gene, but is not limited thereto. The present invention has verified at the cellular level that the drug can effectively knock out or silence the CPA6 gene of the host cell, thereby inhibiting the infection and proliferation of the virus. On this basis, it is also possible to use the drug to perform gene editing on other cells or animals, especially cattle, and achieve the same function.

[0009] The fourth object of the present invention is to provide a bovine kidney cell line in which the CPA6 gene is knocked out or silenced, which has anti-BEV ability and has application prospects in virus isolation and identification and antiviral host factor research.

[0010] A fifth object of the present invention is to provide a method for preparing a bovine kidney cell line in which the CPA6 gene is knocked out or silenced, the method comprising the following steps:

[0011] (1) Design sgRNA sequences and primers targeting the CPA6 gene and construct sgRNA expression plasmids;

[0012] (2) Lentiviral vector packaging of sgRNA expression plasmid;

[0013] (3) Infecting bovine kidney cells containing Cas9 protein with a lentiviral vector packaged with sgRNA expression plasmid to obtain a polyclonal bovine kidney cell line with CPA6 knockout;

[0014] (4) Selecting monoclonal cells from a polyclonal bovine kidney cell line.

[0015] The NCBI accession number of the CPA6 gene is GenBank accession no: 100337371, and the encoded protein sequence is shown in SEQ ID NO.1.

[0016] The present invention successfully constructed CPA6 gene knockout bovine kidney cells using the CRISPR / Cas9 gene editing method. The experimental results showed that the cells can resist BEV infection and reduce the viral titer, and the method has high reproducibility.

[0017] The present invention has the following advantages:

[0018] (1) The present invention identified the function of the CPA6 gene at the cellular level through gain-of-function and loss-of-function experiments, and discovered for the first time that this gene can regulate the host's ability to resist BEV infection. It can be used as a potential target for the design of gene-edited animals for the prevention and treatment of cattle anti-BEV infection, which is of great significance for reducing drug abuse and avoiding epidemics.

[0019] (2) The CPA6 gene is expected to be used as a target for drug design to screen candidate compounds for anti-BEV infection. Test compounds were added to the cell model and the expression level of the CPA6 gene in the cells was detected to screen out test compounds that could significantly reduce the expression level of the CPA6 gene.

[0020] (3) The present invention successfully constructed a CPA6 gene knockout MDBK cell line using CRISPR / Cas9 gene editing technology. This method has the advantages of being simple, fast, low-cost, and having high editing efficiency, and can be used to study host factors related to BEV infection.

[0021] For more detailed technical solutions, please refer to the specific embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1: Schematic diagram of sequencing results of CPA6 knockout MDBK monoclonal cells (CPA6-KO). In the figure: WT is the wild-type MDBK cell sequence, and - represents base deletion.

[0023] Figure 2 : Relative quantitative PCR results of CPA6 knockout MDBK monoclonal cells (CPA6-KO). In the figure: WT is wild-type MDBK, ***p<0.001, mean±SEM (n=3).

[0024] Figure 3 : Results of the EdU cell proliferation level detection of CPA6-knockout MDBK monoclonal cells (CPA6-KO). In the figure: WT is wild-type MDBK, ns indicates no significant difference, mean±SEM (n=3).

[0025] Figure 4 :TCID of CPA6-knockout MDBK monoclonal cells against viruses 50 Verification. In the figure: WT is wild-type MDBK, **p<0.01, ***p<0.001, mean±SEM (n=3).

[0026] Figure 5 : Absolute quantitative qPCR results of the resistance of CPA6 knockout MDBK monoclonal cells to viruses. In the figure: WT is wild-type MDBK, *p<0.05, ***p<0.001, mean±SEM (n=3).

[0027] Figure 6 : Relative quantitative PCR results of CPA6 gene complemented cells. In the figure: WT is wild-type MDBK, ***p<0.001, mean±SEM (n=3).

[0028] Figure 7 :TCID of BEV amplified by CPA6 gene complemented cells 50 Phenotypic verification. In the figure: WT is wild-type MDBK, ***p<0.001, mean±SEM (n=3). DETAILED DESCRIPTION

[0029] The technical scheme of the present invention is further described in detail below in conjunction with specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not used to limit the scope of protection of the claims. Various modifications or equivalent substitutions made by those skilled in the art on the basis of the following examples should also be regarded as falling within the scope of protection of the present invention. The experimental methods for which specific conditions are not indicated in the following examples are usually implemented according to conventional conditions or reference books such as "Molecular Cloning Experiment Guide" (4th edition), or implemented according to the methods recommended in the operating manual provided by the manufacturer. Materials such as MDBK cells, 293T cells, packaging plasmids, T vectors, etc., which are not indicated in the examples, are all commonly used materials known in the art and can be constructed according to literature reports or obtained through commercial channels. The specific information of all plasmids used in this experiment can be queried at http: / / www.addgene.org / , and the restriction plasmid information is pKLV2-U6gRNA5 (BbsI)-PGKpuro2ABFP (#67991), auxiliary plasmids PMD2.G (#12259), PSPAX2 (#12260).

[0030] Example 1: Construction of CPA6 gene knockout MDBK monoclonal cell line

[0031] 1. Recovery and passaging of MDBK cell lines containing Cas9 protein

[0032] First, take out the MDBK cells (MDBK-Cas9) containing Cas9 protein that were previously stored in this laboratory from liquid nitrogen, and quickly put them into a 37°C water bath, shaking continuously during the period to thaw the cells. Put the thawed cells into a sterile operating table, use a pipette to first absorb 5mL of cell culture medium (DMEM containing 5% FBS and 2% double antibody), then absorb the cell suspension, repeatedly blow and beat several times, and inject it into a centrifuge tube. 1000r / min, centrifuge for 5 minutes, and discard the supernatant. Take 2mL of cell culture medium and add it to the centrifuge tube. After repeated blowing and beating, transfer the cells to a six-well plate and culture them in a 37°C, 5% CO2 constant temperature incubator.

[0033] When the cells fill about 95% to 100% of the six-well plate, subculture. The specific operation steps are to take out the six-well plate filled with MDBK-Cas9 cells from the constant temperature incubator, discard the old culture medium, add 1mL PBS to wash, discard PBS, add 1mL trypsin, and incubate in a constant temperature incubator at 37°C and 5% CO2 for 3 minutes. After that, observe whether the cells fall off, add an appropriate amount of cell culture medium and blow repeatedly for more than 10 times, transfer to a 15mL centrifuge tube, 1000r / min, centrifuge for 5 minutes, and discard the supernatant. Add 6mL of cell culture medium, blow and mix, then transfer to 3 wells of the six-well plate, and return to the incubator to continue culturing.

[0034] 2. Design sgRNA sequence targeting CPA6 gene and construct recombinant plasmid

[0035] 2.1 Design of sgRNA sequence targeting CPA6 gene

[0036] As shown in Table 1, a sgRNA was designed based on the CPA6 gene sequence in NCBI (GenBank accession no: 100337371), and a pair of primers was designed for sgRNA for plasmid construction.

[0037] Table 1 sgRNA sequence and plasmid construction primer sequence information

[0038]

[0039] 2.2 sgRNA plasmid construction

[0040] Annealing: Take 5 μL of each of the forward and reverse primers of sgRNA and perform the annealing procedure, namely: denaturation at 95°C for 10 min; annealing at 65°C for 60 min.

[0041] Connect the target fragment to the T vector: Then prepare the reaction system according to Table 2 to carry out the connection reaction between the target fragment and the T vector (company: Takara; product number: 6013), the program is 25°C for 30 min; 65°C for 10 min.

[0042] Table 2 T4 ligase reaction system

[0043]

[0044] Transformation: Take 50 μL of competent cells melted in an ice bath (Company: Beijing Quanshijin Biotechnology; Product No.: CD201), add the above-mentioned ligation product, gently flick to mix, and place in an ice bath for 30 minutes; heat shock in a 42°C water bath for 45 seconds, and then quickly transfer the tube to ice for 2 minutes. Be careful not to shake the centrifuge tube during this process; add 500 μL of sterile LB culture medium to each centrifuge tube, mix well, and place in a shaker at 37°C, 200rpm for 1 hour to allow the bacteria to recover; then centrifuge at 4000rpm for 5 minutes, discard 350 μL of supernatant, and resuspend the transformed competent cells in the remaining 200 μL, add to the LB agar plate containing ampicillin resistance, spread the cells evenly, and after the liquid is absorbed, invert the plate and culture it at 37°C overnight.

[0045] Monoclonal detection: Pick a single clone and add it to LB liquid culture medium containing ampicillin resistance, place it in a shaker at 37°C and 200rpm for expansion culture for about 4-5 hours, and mix it well. Take 200μL of bacterial solution and send it to Qingke for sequencing.

[0046] Extraction of sgRNA expression plasmid: The sgRNA expression plasmid was extracted from the successfully sequenced monoclonal bacterial solution according to the plasmid extraction kit (company: OmegaBio-Tek; catalog number: D6950-02).

[0047] 3. Obtaining a CPA6-knockout MDBK polyclonal cell line

[0048] 3.1 Lentiviral packaging of sgRNA expression plasmid

[0049] Recovery and culture: 293T cells were revived in a 10 cm cell culture dish and passaged after confluence. 293T cells with good growth status of about 3 generations (10 cm cell culture dish, 90%-95% confluence, fresh antibiotic-free DMEM medium containing 10% FBS) were taken for lentiviral packaging.

[0050] Transfection: Before transfection, discard the old culture medium, add DMEM culture medium containing 5% FBS and 1% penicillin-streptomycin double antibody and continue to return to the incubator for culture (consider washing with PBS when there are many floating cells); for a 10cm cell culture dish, the total amount of plasmid during lentivirus packaging is 24μg, of which (PMD2.G: PSPAX2: sgRNA expression plasmid = 1:2:3); add the corresponding volume of plasmid to 500μL Jetprime Buffer in sequence, gently blow and mix, add 40μL JetprimeRegent, gently blow and mix, let stand at room temperature for 10min, then add to the culture dish, shake gently and return to the incubator; 4-6h after virus packaging, change 10mL of DMEM culture medium containing 5% FBS and 1% double antibody, return to the incubator for continued culture; 24h after the change of medium, add 10mL of DMEM culture medium containing 5% FBS and 1% double antibody, mix well and return to the incubator.

[0051] Ultracentrifugation: After 60-72 hours of virus packaging, observe the cell morphology, collect the cell supernatant (one 50mL centrifuge tube for every 2 10cm cell culture dishes), seal with sealing film, centrifuge at 3000rpm / min at 4℃ for 10min, filter the supernatant with a 0.45μm filter into an ultracentrifuge tube, and then ultracentrifuge at 30000rpm at 4℃ for 2.5h; then pour out the supernatant, turn it upside down on absorbent paper to absorb the residual liquid, add 120μL pre-cooled PBS to each tube to resuspend, blow it open and mix it completely, then transfer the same virus concentrate to the same collection tube and disperse it overnight at 4℃; according to the demand of later experiments, divide it into aliquots and store it at -80℃.

[0052] 3.2sgRNA lentiviral transfection of MDBK-Cas9 cell line

[0053] MDBK-Cas9 was revived in a six-well plate, and after it was full, it was subcultured at a ratio of 1:3. When the cells were full to about 60%, the old culture medium was discarded, and 1 mL of cell maintenance solution (DMEM containing 2% FBS + 1% double antibody) was added to each well, followed by 1 μL of polybreme, and then 40 μL of sgRNA lentivirus was added and mixed. After incubation for 24 hours, the old culture medium was discarded, and 2 mL of culture medium containing 5% FBS and 1% double antibody was added. After another 24 hours of incubation, 2 mL of DMEM culture medium containing 5% FBS, 1% double antibody and 2 μg / mL puromycin was replaced for drug screening. After all the negative control drug screening wells died, the positive control and negative control were subcultured (Note: the positive control wells were subcultured in a six-well plate at a ratio of 1:2, and the negative control was subcultured in two wells, one of which was used as the negative control drug screening group). In this way, the drug screening effect lasted for a total of 7 days to obtain the MDBK polyclonal cell line with CPA6 knockout.

[0054] 4. Selection of CPA6-knockout MDBK monoclonal cells

[0055] The CPA6 knockout MDBK polyclonal cell line was revived in a six-well plate, and the cells were counted after they were full. 100 cells were spread on a 96-well plate, and each sgRNA knockout cell line was spread on 2 96-well plates. The cell medium (containing 10% FBS + 1% double antibody DMEM) was changed every 5 days, and the cells were observed daily. The cells that filled a well with one cell were digested and transferred to a six-well plate. Some of them were expanded and frozen, and some were extracted using the TIANamp Genomic DNA Kit.

[0056] The extracted DNA was subjected to PCR amplification. The primer sequences are shown in Table 3. The PCR reaction system was prepared according to Table 4. The program was 98°C pre-denaturation for 5 min, cycle number 1; 98°C denaturation for 10 s, 57°C annealing for 15 s, 72°C extension for 30 s, cycle number 35; and finally 72°C extension for 5 min. The PCR product was sent to Qingke Bio for sequencing, and the mutation type was determined compared with the wild-type MDBK. The sequencing results are shown in Figure 1 As shown, the CPA6 knockout MDBK cell line numbered CPA6-KO has an 11-base deletion.

[0057] Table 3 Primer sequence information for amplifying target fragments

[0058]

[0059] Table 4 PCR amplification reaction system

[0060]

[0061]

[0062] Example 2: Verification of transcriptional levels in CPA6 knockout MDBK monoclonal cells

[0063] The RNA was extracted from wild-type MDBK and CPA6 knockout monoclonal cell lines numbered CPA6-KO by Trizol method, and reverse transcribed into cDNA by reverse transcription kit (company: Nanjing Novezan Biotechnology Co., Ltd.; catalog number: R223-01). Relative quantitative qPCR was performed to verify the expression of CPA6 transcription level. The primer sequences of relative quantitative qPCR are shown in Table 5. The relative quantitative qPCR reaction system was prepared according to Table 6. The program was 95℃ pre-denaturation for 5min, cycle number 1; 95℃ denaturation for 10s, 60℃ annealing for 30s, and the instrument default melting curve. The results are shown in Table 5. Figure 2 It was shown that compared with wild-type MDBK cells, the expression level of CPA6 knockout monoclonal cell line numbered CPA6-KO was significantly decreased at the transcriptional level.

[0064] Table 5 Relative quantitative qPCR primer sequence information

[0065]

[0066] Table 6 Relative quantitative qPCR amplification reaction system

[0067]

[0068] Example 3: Verification of EdU cell proliferation level in CPA6 knockout MDBK monoclonal cells

[0069] To evaluate the cell proliferation level after CPA6 knockout, wild-type MDBK and CPA6-KO knockout cell lines were cultured at 5 × 10 5 Cells were seeded into 6-well plates. The cells were transferred into DMEM medium supplemented with 10% FBS and 1% double antibody and incubated in an incubator at 37°C and 5% CO2. After incubation for 24 hours, BeyoClick with Alexa Fluor 555 (Company: Beyotech; Product No.: C0075s) was used to TM EdU cell proliferation assay was performed using the EdU cell proliferation kit, and cell nuclei were stained with DAPI (company: Bio-Tech; catalog number: C1005) for 10 min at room temperature and in the dark. Stained cells were observed using a fluorescence microscope. The ratio of EdU positive cells was calculated using Image J software. Imaging was performed on three independent wells, and one field of view was randomly captured from each well. The results are shown in Figure 2. Figure 3 The results showed that the proliferation ability of CPA6 knockout cells was not significantly changed compared with wild-type MDBK cells, and this cell line can be used for subsequent validation experiments.

[0070] Example 4: Using TCID50 Absolute quantitative qPCR detection of anti-BEV ability of knockout cells

[0071] The wild-type MDBK and CPA6-KO knockout cell lines were revived in T25 cell flasks, and the cells were counted after they grew to full size. 3.5×10 6 The cells were plated in T25 cell flasks and counted after 24 hours of attachment. Then, the cells were inoculated with BEV at 0.1 MOI. The culture supernatant and the culture supernatant + cell mixture were collected 12, 24 and 36 hours after inoculation, and the TCID of BEV in the wild-type MDBK and knockout cell line samples numbered CPA6-KO were detected. 50 , and observe their phenotypic differences. Figure 4 It was shown that after infection with BEV, the viral titer of the CPA6 knockout cell line was significantly reduced compared with that of wild-type MDBK.

[0072] The viral RNA was extracted using a viral RNA extraction kit (company: Nanjing Novezan Biotechnology Co., Ltd.; catalog number: RM402-01) to determine the viral TCID 50 Viral RNA was extracted from the virus sample after PCR, and the RNA was reverse transcribed into cDNA using a reverse transcription kit (Company: Nanjing Novezan Biotechnology Co., Ltd.; Catalog No.: R223-01). The cDNA product was used as a template for absolute quantitative qPCR. The primer sequences for absolute quantitative qPCR are shown in Table 7. The absolute quantitative qPCR reaction system was prepared according to Table 6 above. The amplification program was: 95℃ pre-denaturation for 5min, cycle number 1; 95℃ denaturation for 10s, 60℃ annealing for 30s, and the instrument default melting curve. The results are shown in Figure 5 Display, same as TCID 50 The measurement results were consistent. Compared with wild-type MDBK, the BEV virus copy number in CPA6 knockout cell lines was significantly reduced.

[0073] Table 7 Absolute quantitative qPCR primer sequence information

[0074]

[0075] Example 5: CPA6 gene complementation verification

[0076] 1. Construction of CPA6 gene complementation plasmid

[0077] RNA was extracted from wild-type MDBK cells, and cDNA was obtained by inversion. The cDNA was used as a template, and the CPA6 target gene was amplified using homologous recombination primers according to the above Table 4 to configure the PCR reaction system. The Flag tag was added before the stop codon at the end of the target sequence; the amino acid near the NGG position of the sgRNA was mutated to a synonymous amino acid to obtain the CPA6 gene complementation sequence. The pLVX-EGFP-IRES-Neo vector was double-digested with EcoRI (Company: New England Biolabs; Product No.: R0101V) and BamHI (Company: New England Biolabs; Product No.: R0136V), and the 8269bp vector band was recovered. The target band and the vector band were connected using homologous recombination enzyme (Company: Nanjing Novezan Biotechnology Co., Ltd.; Product No.: C112-01) to construct the pLVX-c CPA6-flag complementation plasmid. The connection was carried out overnight at 4°C, and the bacteria were picked for identification and sequenced to obtain the pLVX-c CPA6-flag complementation plasmid. The endotoxin-free plasmid was extracted using a plasmid mini-extraction kit (company: Omega Bio-Tek; catalog number: D6950-02) and stored at -80° C. The restriction enzyme digestion reaction system of the pLVX-EGFP-IRES-Neo vector is shown in Table 8, and the restriction enzyme digestion ligation system of the complemented sequence fragment and the vector is shown in Table 9.

[0078] Table 8 Enzyme Digestion Reaction System

[0079]

[0080] Table 9 Recombination system of complemented sequence fragments and vector restriction enzyme digestion

[0081]

[0082] 2. Obtaining CPA6 complementation cell line

[0083] Refer to the method of step 3.1 of Example 1 to package the pLVX-c CPA6-flag complementing plasmid with lentivirus, that is, replace the "sgRNA expression plasmid" in the step with the above-mentioned pLVX-c CPA6-flag complementing plasmid.

[0084] The knockout cell line CPA6-KO was revived in a six-well plate, and after it was full, it was subcultured at a ratio of 1:3. When the cells were full to about 60%, the old culture medium was discarded, and 1 mL of cell maintenance solution (DMEM containing 2% FBS + 1% double antibody) was added to each well, followed by 1 μL of polybreme, and then 40 μL of CPA6 complement plasmid lentivirus was added and mixed. After incubation for 24 hours, the old culture medium was discarded, and 2 mL of culture medium containing 5% FBS and 1% double antibody was added. After another 24 hours of incubation, 2 mL of DMEM culture medium containing 5% FBS, 1% double antibody and 400 μg / mL neomycin was replaced for drug screening. After all the negative control drug screening wells died, the positive control and negative control were subcultured (Note: the positive control wells were subcultured in a six-well plate at a ratio of 1:2, and the negative control was subcultured in two wells, one of which was used as the negative control drug screening group). In this way, the drug screening effect lasted for a total of 7 days to obtain the CPA6 complemented MDBK cell line. Total RNA of the complemented cells was extracted using Trizol, and the relative quantitative method according to Example 2 was used to verify whether the complementation experiment was successful. The results are as follows: Figure 6 It showed that the CPA6 gene was successfully complemented.

[0085] 3. Phenotypic Identification of CPA6 Complementary Cell Lines

[0086] Referring to Example 4, wild-type MDBK cells and CPA6 complemented cells were infected with BEV virus, and TCID 50 To verify whether the phenotype has been restored, the results are as follows Figure 7 The results showed that after CPA6 gene complementation, the transcription level of CPA6 gene in the complemented cell line was significantly higher than that in the wild-type MDBK, and the complemented cells restored their susceptibility to BEV.

Claims

1. Application of CPA6 protein or a gene encoding the protein in regulating host antiviral activity, wherein the virus is bovine enterovirus (BEV).

2. The use according to claim 1, characterized in that: Knocking out or silencing the CPA6 gene can improve the host's resistance to infection and inhibit BEV proliferation, while restoring the CPA6 gene makes the host susceptible to BEV.

3. Use of an agent for knocking out or silencing the CPA6 gene in the preparation of anti-BEV drugs and animal cells or varieties.

4. An anti-BEV drug comprising an agent for knocking out or silencing the CPA6 gene.

5. The anti-BEV drug according to claim 4, characterized in that: The reagent includes a Cas9 gene editing protein or an expression vector thereof, and a gRNA or an expression vector thereof that guides the Cas9 gene editing protein to specifically bind to the CPA6 gene.

6. A BEV-resistant bovine kidney cell line, wherein the CPA6 gene of the bovine kidney cell line is knocked out or silenced, and the expression of the endogenous CPA6 gene is absent or the expression level is reduced, thereby having anti-BEV ability.

7. A method for preparing an anti-BEV bovine kidney cell line, characterized in that The following steps are involved: (1) Design sgRNA sequences and primers targeting the CPA6 gene and construct sgRNA expression plasmids; (2) Lentiviral vector packaging of sgRNA expression plasmid; (3) using a lentiviral vector containing an sgRNA expression plasmid to infect bovine kidney cells containing the Cas9 protein, and obtaining a polyclonal bovine kidney cell line in which the CPA6 gene was knocked out; (4) Monoclonal cells were selected from the polyclonal bovine kidney cell line in which the CPA6 gene was knocked out.

8. The method for preparing the anti-BEV bovine kidney cell line according to claim 7, characterized in that: The amino acid sequence encoded by the CPA6 gene is shown in SEQ ID NO.

1.

9. The method for preparing the anti-BEV bovine kidney cell line according to claim 8, characterized in that: The sgRNA sequence is shown as SEQID NO.

2.

10. The method for preparing the anti-BEV bovine kidney cell line according to claim 9, characterized in that: The primer sequences are shown in SEQ ID NO.3 and 4.

Citation Information

Patent Citations

  • Preparation method and application of carboxypeptidase A with function of degrading ochratoxin A

    CN109666664A

  • Method for establishing bovine kidney cell inflammation model by infecting bovine enterovirus in vitro

    CN115369068A

  • New targets for RNA therapeutics

    US20180126003A1